An update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients

Basit Öğe Kaydı
dc.contributor.authorOruc, Zeynep
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorArslan, Cagatay
dc.date.accessioned2024-04-24T17:07:47Z
dc.date.available2024-04-24T17:07:47Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: Bone metastases in breast cancer patients are a common clinical problem. Many factors influence the treatment decision, including tumor characteristics, previous treatment and tumor burden in the treatment of metastatic breast cancer. Areas covered: This present review summarizes the new treatment strategies and the chemotherapeutic agents currently available in the management of metastatic breast cancer with bone metastases. Expert opinion: Patients with bone metastases more often have hormone receptor-positive tumours. Although new treatment agents for metastatic breast cancer have been investigated, endocrine therapy is still considered as the treatment of choice for patients with bone metastases although chemotherapy still has an important place. In recent years, new chemotherapeutic agents such as etirinotecan and nab-paclitaxel have been established though there are few studies that have looked at particular types of metastases. In the last decade, therapies for bone metastasis resistant to endocrine therapy have predominantly focused on radiotherapy, surgical resection, chemotherapy, bone-targeting radiopharmaceuticals and targeted therapeutics. New targeted agents include: Src inhibitors, cathepsin K inhibitors, CXCR4 inhibitors, TGF-B blockade and integrin antagonists while drug delivery systems for chemotherapy have also been developed. These new treatment options could be future treatment options for bone metastatic disease if early promising results are confirmed by clinical trials.en_US
dc.identifier.doi10.1080/14656566.2018.1504922
dc.identifier.endpage1316en_US
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.issue12en_US
dc.identifier.pmid30129373
dc.identifier.scopus2-s2.0-85052945196
dc.identifier.scopusqualityQ2
dc.identifier.startpage1305en_US
dc.identifier.urihttps://doi.org/10.1080/14656566.2018.1504922
dc.identifier.urihttps://hdl.handle.net/11468/16984
dc.identifier.volume19en_US
dc.identifier.wosWOS:000443869900002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Opinion on Pharmacotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone Metastasisen_US
dc.subjectBreast Canceren_US
dc.subjectChemotherapyen_US
dc.subjectTargeted Therapyen_US
dc.subjectDrug Delivery Systemsen_US
dc.titleAn update on the currently available and future chemotherapy for treating bone metastases in breast cancer patientsen_US
dc.titleAn update on the currently available and future chemotherapy for treating bone metastases in breast cancer patients
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu